Log In
Print
BCIQ
Print
Print this Print this
 

MKC1106-MT

  Manage Alerts
Collapse Summary General Information
Company MannKind Corp.
DescriptionActive immunotherapy consisting of a DNA plasmid and 2 synthetic peptides administered separately, which target 2 tumor-specific antigens
Molecular Target
Mechanism of ActionImmunotherapy
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase II
Standard IndicationMelanoma
Indication DetailsTreat advanced melanoma
Regulatory Designation

Partner

Colby Pharmaceutical Co.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today